Wave Life Sciences (WVE) Director Ken Takanashi Sells Shares

What Happened

• Ken Takanashi, a director of Wave Life Sciences (WVE), sold 3,864 shares of common stock on August 11, 2026.
• The sales were for a weighted-average price of $6.01 per share (total proceeds ≈ $23,223); reported sale price range was $6.01–$6.03 per share.
• The filing states the shares were sold solely to cover taxes associated with restricted stock units that vested on August 11, 2026, and the transactions were made pursuant to a previously adopted 10b5-1 trading plan — a routine tax-withholding transaction rather than an opportunistic market sale.

Key Details

• Transaction date: August 11, 2026. Form 4 filed: August 13, 2026 (filed on time under Section 16 rules).
• Transaction type: Sale (code S). Weighted-average price: $6.01; price range: $6.01–$6.03.
• Amount sold: 3,864 shares; proceeds ≈ $23,223.
• Shares owned after the transaction: not specified individually in the filing. The filing notes aggregate holdings held by entities SNBL USA, Ltd. (6,107,593 shares) and Shin Nippon Biomedical Laboratories, Ltd. (3,498,815 shares) and states Mr. Takanashi disclaims beneficial ownership of those entity-held shares except to the extent of any pecuniary interest.
• Notable footnotes: sale was solely to cover tax withholding on RSU vesting; sales executed under a pre-established 10b5-1 plan; reporting person will provide detailed per-price sale breakdown upon request.
• Additional filing items: Exhibit 24.1 (Power of Attorney); company remark that Wave redomiciled from Singapore to Delaware effective Aug 7, 2026 (no change to shareholder proportions).

Context

• Tax-withholding sales associated with RSU vesting and executed under 10b5-1 plans are routine and typically do not signal a change in insider sentiment. This was not an open-market purchase or a discretionary sale outside a pre-established plan.
• Mr. Takanashi is a director and is linked to large aggregate holdings via SNBL-affiliated entities, though he disclaims beneficial ownership of those entity-held shares per the filing.